1 Immunoglobulin G glycome composition in transition from pre-menopause to menopause

2

3 Domagoj Kifer¹, Helena Deriš², Ana Cindrić², Tea Petrović², Ana Cvetko¹, Irena Trbojević-
4 Akmačić², Louise Newson³, Tim Spector⁴, Cristina Menni⁴, and Gordan Lauc^{1,2}

5

6

7 ¹Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb 10000, Croatia

8

9 ²Genos Glycoscience Research Laboratory, Zagreb 10000, Croatia

10

11 ³Newson Health Menopause & Wellbeing Centre, Church Street Stratford-Upon-Avon

12

13 CV37 6HB, UK

14

15 ⁴Department of Twin Research and Genetic Epidemiology, King's College London,

16

17 Westminster Bridge Road, SE17EH London, UK

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

16 **Abstract**

17 Background

18 Glycosylation of immunoglobulin G (IgG) is an important regulator of the immune system
19 and its changes are believed to be a significant contributor to inflammaging. Gonadal
20 hormones affect IgG glycome composition, suggesting that alterations in IgG glycosylation
21 might be one of the molecular mechanisms behind increased disease risk in perimenopause.

22 Methods

23 IgG was isolated from 5,354 plasma samples collected from 1,940 females and 113 males at
24 multiple time points. IgG glycans were released, labelled with a fluorescent dye and
25 analysed by ultra-high-performance liquid chromatography. Mixed modelling was used to
26 determine average levels of individual IgG glycans in pre-menopausal women, menopausal
27 women, and men.

28 Findings

29 Large and statistically significant differences in IgG glycome composition were observed,
30 mainly reflecting decreased galactosylation and sialylation of glycans in menopausal
31 women. During perimenopause women had a significant higher rate of increase in
32 agalactosylated structures (0.051/yr; 95%CI = 0.043 - 0.059, $p < 0.001$), and decrease in
33 digalactosylated (-0.043/yr; 95%CI = -0.050 – -0.037, $p < 0.001$), and monosialylated glycans (-
34 0.029/yr; 95%CI = -0.034 – -0.024, $p < 0.001$), compared to premenopausal women.

35 Interpretation

36 Proinflammatory IgG glycome and the resulting decrease in the ability of IgG to suppress
37 low-grade chronic inflammation may be an important molecular mechanism mediating the
38 increased health risk in perimenopause. IgG glycome changes considerably during
39 perimenopause and may aid the diagnosis of perimenopause.

40 Funding

41 Croatian National Centre of Excellence in Personalised Healthcare, ESI Funds grant for the
42 Centre of Competences in Molecular Diagnostics, the Wellcome Trust and the Medical
43 Research Council (MRC)/British Heart Foundation (BHF).

44

45 Introduction

46 Glycosylation of immunoglobulin G (IgG) is an important regulator of the immune system ¹.
 47 In addition to directly affecting the effector functions of IgG by promoting its binding to
 48 different Fc receptors ², glycans attached to IgG have numerous other roles in the regulation
 49 of the immune system ^{3,4}. Glycans are also important mediators of the anti-inflammatory
 50 activity of IgG ^{5,6} as well as the driving force for one of the molecular mechanisms underlying
 51 immunosuppressive activity of intravenous IgG (IVIG) therapy used to treat a variety of
 52 immunological disorders ⁷. Changes in IgG glycosylation are also believed to be an important
 53 contributor to aging at the molecular level through a process called inflammaging ⁸.

54 IgG glycome composition is tightly regulated and, despite the absence of a direct genetic
 55 template, is heritable to a significant extent ^{9,10}. Alternative glycosylation (the attachment of
 56 different glycan structures to the same glycosylation site) is structurally and functionally
 57 analogous to coding mutations, but instead of being defined by sequence variation in
 58 individual genes, glycome composition is inherited as a complex trait encoded by multiple
 59 genes ¹¹. Genome-wide association studies identified a network of over 30 genes that
 60 associate with the IgG glycome composition ¹²⁻¹⁴. One of the regulators of IgG glycosylation
 61 are sex hormones, and the association between estradiol and the IgG glycome composition
 62 was confirmed to be causal ¹⁵. Recent randomised placebo-controlled clinical study
 63 demonstrated that the deprivation of gonadal hormones resulted in an increase of
 64 biological age measured by IgG glycans, which was completely prevented by estradiol
 65 supplementation ¹⁶.

66 Large population studies revealed that IgG glycome composition changes with age and that
 67 in females this change is particularly pronounced in the time preceding the average age of
 68 menopause ^{17,18}. However, the association between changes in the IgG glycome
 69 composition and menopause has not yet been validated. Perimenopause is accompanied by
 70 different symptoms and is very often misdiagnosed due to changing hormone levels and
 71 symptom overlap with other conditions. Menopause associates with an increased risk of
 72 developing a range of diseases affecting metabolism, bones, cardiovascular system, brain,
 73 even cancer ¹⁹. Early perimenopause diagnosis would enable timely interventions to ease
 74 the symptoms, decrease risks of developing accompanying diseases, and timely monitoring
 75 of any changes in women's health status due to hormonal changes. To fill this knowledge
 76 gap and explore the association of IgG glycome changes with perimenopause, we analysed
 77 IgG N-glycome composition in 5,080 samples from 1,940 females in multiple time points
 78 during their transition from pre-menopause to menopause, along with 274 samples from
 79 113 males as an additional control.

80

81

82 **Methods**

83 Study population

84 Study subjects were individuals enrolled in the TwinsUK registry, a national register of adult
85 twins recruited as volunteers without selecting for any particular disease or traits²⁰. Data on
86 menopause was gathered through the multiple choice questionnaire asking women at each
87 visit: "What is your menopausal status?" with possible answers "Pre menopausal", "Going
88 through the menopause", "Post menopausal" and "Don't know" and "How old were you
89 when you became post-menopausal (when you stopped having periods for one year or
90 more)?" Consequently sample was defined as menopausal if questionar resulted with
91 "Post-menopausal" answer or age larger then reported age of becoming postmenopausal.
92 Similarly sample was defined as premenopausal if questionnaire resulted with "Pre
93 menopause" answer of age at sampleing was less then reported age of becoming
94 postmenopausal reduced by 1 year. Any inconsistent (i.e. "Pre menopausal" answer at age
95 after becoming menopausal) or unreliable data (i.e. answered as "Going through the
96 menopause") were dropped from the study (Supplementary Table 1). The TwinsUK study
97 was approved by NRES Committee London–Westminster, and all twins provided informed
98 written consent.

100 Isolation of IgG

101 IgG isolation from serum samples was performed on protein G monolithic 96-well plates as
102 previously described²¹. In brief, 100 µL of serum was diluted 1:7 (v/v) with PBS (phosphate
103 buffer saline) followed by filtration on a 0.45 µm GHP filter plate (Pall Corporation, USA).
104 Diluted and filtered serum samples were then transferred to the protein G monolithic plate,
105 which was then washed. Elution of IgG was performed with 1 mL of 0.1 mol/L formic acid
106 (Merck, Germany) followed by immediate neutralization of the mixture with ammonium
107 bicarbonate (Acros Organics, USA) to pH 7.0. IgG-containing eluate was aliquoted into PCR
108 plate (average mass of 15 µg of IgG per sample) and dried in a vacuum centrifuge.

110 Deglycosylation, labelling and purification of IgG N-glycans

111 Deglycosylation, RapiFluor-MS labelling and purification of IgG N-glycans were performed
112 using the GlycoWorks RapiFluor-MS N-Glycan Kit obtained from Waters Corporation (USA).
113 The entire procedure was done following Waters' protocol (Waters Corporation 2017,
114 <https://www.waters.com/webassets/cms/support/docs/715004793en.pdf>). In the end, the
115 samples of released and labelled IgG glycans were stored at -20 °C until further use.

117 HILIC-UHPLC-FLR analysis of RapiFluor-MS labelled IgG N-glycans

118 RapiFluor-MS labelled IgG N-glycans were analysed using ultra-high-performance liquid
119 chromatography based on hydrophilic interactions with fluorescence detection (HILIC-
120 UHPLC-FLR) on Waters Acquity UPLC H-class instruments. The instruments were controlled
121 and monitored with the Empower 3 software, build 3471 (Waters, USA). Chromatographic
122 separation of glycan structures was performed on Waters UPLC Glycan bridged ethylene
123 hybrid (BEH) Amide chromatographic columns (130 Å, 1.7 µm BEH particles, 2.1x100 mm).
124 Solvent A was 50 mmol/L ammonium formate, pH 4.4, while solvent B was 100% LC-MS
125 grade acetonitrile. A linear gradient of 75–61.5 % acetonitrile (v/v) was used at a flow rate
126 of 0.4 mL/min over 30 minutes in a 42-minute analytical run. Each chromatogram was
127 separated into 22 glycan peaks containing IgG glycan structures (**Supplementary Figure 1.**),
128 by automated integration²² resulting in relative quantification of IgG N-glycans (total area

normalization). Specific N-glycan structures found in each glycan peak according to Keser et al.²³ are presented in **Supplementary Table 2**. Formulas used for the calculation of IgG derived traits are presented in **Supplementary Table 3**.

Statistical analysis

After UHPLC analysis, each measured glycan peak was normalized by total chromatogram area. Observed relative glycan abundances were log transformed and batch corrected using ComBat method (R package 'sva'²⁴). After batch correction, values were back-transformed to relative abundance and derived traits were calculated according to **Supplementary Table 3**.

Overlapping measured N-glycomes and information available on menopause found in TwinsUK register, resulted in 5354 samples from 1940 females and 113 males.

For each glycan trait the effect of menopause on the abundance was estimated by mixed modelling (R package 'lme4'²⁵). Logit transformed relative abundance was used as dependent variable and sex, menopausal status (nested within sex), age and age-menopausal status interaction as fixed factors, as well as family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Using model, mean values were estimated for each group and pairwise compared using t-test (post-hoc) (R package 'emmeans'²⁶). Given multiple testing for large number of glycans, the control of false discovery rate (FDR) was done by adjusting p values according to Benjamini-Hochberg's method.

For the analysis of the rate of change of glycan abundances, average yearly changes were calculated from two timepoints according to the formula: $\text{rate} = (\text{logit}(\text{glycan}_2) - \text{logit}(\text{glycan}_1)) / (\text{age}_2 - \text{age}_1)$, where glycan is relative abundance resulted from normalized chromatogram, and age is represented in years, assuming $\text{age}_2 > \text{age}_1$. Depending on menopausal status in the first and second timepoint measurements were classified into three categories: premenopausal (both timepoints before menopause), perimenopausal (first timepoint before, and second in the menopause), and menopausal (both timepoints in menopause). Mean rates were estimated by the mixed model, in which rate was dependent variable, and sex, menopausal group (nested within menopausal status) and mean age (calculated as $(\text{age}_2 + \text{age}_1) / 2$) were set as fixed factors, as well as family ID and individual ID (nested within family ID) as random intercepts. Estimated mean rates for each menopausal group and males were pairwise compared using t-test (post-hoc). FDR control was done by adjusting p values according to Benjamini-Hochberg's method.

N-glycome (observed in one timepoint) potential for diagnosis of perimenopause was analysed in a subset of women aged between 45 and 55 years by logistic regression with L1 regularization technique (R package 'caret' and 'glmnet'^{27,28}). The subset was split into training (randomly chosen one measurement per family) and test (everything else) subset. The logistic model was defined with menopausal status (TRUE/FALSE) as the dependent variable, and age and all directly measured glycans as independent variables. To avoid overfitting, coefficients of the logistic model were estimated by 10-fold cross validation on training subset data, with hyperparameter lambda set to $\lambda_{\min}$. The model was tested on test subset; results are presented by receiver operating characteristic (ROC) curve. In parallel, the null model was fitted in the same way but using only age as a predictor. Observed ROC curves of the two models were compared by a bootstrap test ($B = 2000$) (R package 'pROC'²⁹).

The rate of N-glycome change (based on two timepoints) potential for diagnosis of perimenopause was analysed in a subset of women with median two-timepoint age between 45 and 55 years in the same way as diagnosis of menopause with IgG glycome analysed in one timepoint. The perimenopausal category was defined as TRUE, while others (menopausal and premenopausal) were defined as FALSE. All statistical analyses were done using R³⁰.

Results

IgG glycome composition was analysed in multiple samples from 1,940 females and 113 males from the UK registry of adult twins. The 1,087 samples from 732 individual twins (500 families) were collected prior to the onset of menopause, while 3,993 samples from 1,678 individual twins (969 families) were collected after the onset of menopause (Supplementary Table 1). Additionally, IgG glycome was analysed in 113 men (274 samples) as an additional control. A representative chromatogram with detailed structures of individual IgG glycans is shown in Supplementary Figure 1. Mixed modelling was used to determine average levels of individual IgG glycans in pre-menopausal women, menopausal women, and men. Large and statistically significant differences were observed in multiple glycans, mainly reflecting decreased galactosylation and sialylation of glycans in menopausal women (Figure 1). Levels of individual IgG glycans are available in Supplementary Figure 2.

Figure 1. IgG glycome composition in premenopausal women, menopausal women, and men. Mean glycan abundances (% of total IgG glycome) and corresponding 95% confidence intervals were estimated from fitted mixed model with logit transformed glycan as dependent variable and sex, menopausal status (nested within sex), age and age-menopausal status interaction as fixed factors, as well as family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p values less than 0.1 are shown. B - bisecting N-acetylglucosamine (GlcNAc), CF - core fucose, G0 - agalactosylated glycans, G1 - monogalactosylated glycans, G2 - digalactosylated glycans, S1 - monosialylated glycans, and S2 - disialylated glycans.

It is known that IgG galactosylation and sialylation decrease with age¹⁷ thus we attempted to evaluate whether the changes in glycans associated with the transition to menopause were more extensive than the age-related changes. Since we had multiple samples from the same individual, we were able to calculate the rate of change of individual IgG glycans through time. A subset of women in our cohort (n = 379) entered menopause between two sampling time points, thus for them, we were also able to calculate the rate of changes in individual IgG glycans during the perimenopausal period. The comparison of the rate of age-related IgG glycome changes (when there was no change of the menopause status) with the rate of IgG glycome changes during perimenopause (i.e., between time points when the transition to menopause occurred) revealed statistically significant differences for a number of glycans (Supplementary Figure 3). The most prominent differences in the perimenopause period were the significantly larger rates of increase in the agalactosylated structures (G0) and the decrease of digalactosylated (G2) and monosialylated (S1) glycans (Figure 2). During perimenopause women had a significant higher rate of increase in agalactosylated structures (0.051/yr; 95%CI = 0.043 - 0.059, p<0.001), and decrease in digalactosylated (-0.043/yr; 95%CI = -0.050 - -0.037, p<0.001), and monosialylated glycans (-0.029/yr; 95%CI = -0.034 - -0.024, p<0.001), compared to premenopausal women.

Figure 2. Average yearly change of IgG glycans in females during the perimenopause period, females in pre- or post-menopause, and males. Mean yearly change in IgG glycan abundances and corresponding 95% confidence intervals were estimated from fitted mixed model with logit transformed glycan as dependent variable and sex, menopausal status (nested within sex), age and age-menopausal status interaction as fixed factors, as well as

family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p values less than 0.1 are shown. B - bisecting GlcNAc, CF - core fucose, G0 - agalactosylated glycans, G1 - monogalactosylated glycans, G2 - digalactosylated glycans, S1 - monosialylated glycans, and S2 - disialylated glycans.

Using single-point measurements of IgG N-glycans we attempted to predict menopause status. The lasso model was fitted with menopausal status (TRUE for those who entered menopause and FALSE for all others) as dependent variable and age and all directly measured IgG glycans as predictors. The model was fitted on a randomly chosen one twin per family (training set) in the subset of women with a two-timepoint median age between 45 and 55 years. The remaining twins were used for testing the fitted model. The same train and test subset model with only mean age as a predictor were used to fit and test the model for comparison (Figure 3A). IgG N-glycome in combination with age measured in a single timepoint has shown a good classification performance, with the AUC of 0.853 (95% CI 0.823-0.880) outperforming only age as a predictor of perimenopause (AUC of 0.818, 95% CI 0.783-0.849).

Since changes in the IgG glycome composition were the most prominent in the period of perimenopause, we used the rate of changes in glycans to predict whether a given woman already entered the period of perimenopause, or not (Figure 3B). The model was fitted on a randomly chosen one twin per family (training set) in the subset of women with a two-timepoint median age between 45 and 55 years. The remaining twins were used for testing the fitted model. The addition of the information about changes in the IgG glycan levels to a prediction model notably increases AUC value compared to using only age (0.694, 95% CI 0.637-0.751 compared to 0.507, 95% CI 0.443-0.570, respectively).

Figure 3. . Receiver operating characteristic (ROC) curves for the prediction of perimenopause using IgG glycans measured in a single time point (A) and the change in IgG glycan levels between the two timepoints (B). Graphs are showing area under the curve (AUC) values with 95% confidence intervals.

Discussion

In this study we have shown the association between the period of perimenopause and the extensive changes in the IgG glycome composition. Aging continuously associates with the transition of the IgG glycome from an inflammation-suppressive to a proinflammatory composition, but this change is much faster in the period when women are progressing from a regular cycle to menopause. The depletion of estrogen during perimenopause and menopause is an important event of aging since low hormone levels increase vulnerability to diseases in hormone-responsive tissues, including the brain, bone, and the cardiovascular system. Menopause is therefore more complex than just being a natural condition resulting in symptoms; it needs to be considered as a long-term hormone deficiency leading to health risks if not appropriately managed with lifestyle adjustments or hormone replacement therapy (HRT)³¹. After entering menopause, there is an increased risk of developing obesity and metabolic disease, cardiovascular diseases, osteoporosis and arthritis, dementia and cognitive decline, and cancer¹⁹.

Previous population studies revealed that IgG N-glycome composition changes with age, especially in females in the time preceding the average age of menopause^{17,18}. In this study we used multiple samples from the same individuals to confirm the association between perimenopause and the extensive changes in the IgG glycome composition. The most extensive change in the IgG glycome during perimenopause was a decrease in galactosylation and sialylation, a change that is generally associated with aging¹. Aging continuously associates with the transition of the IgG N-glycome from an inflammation-suppressive to a proinflammatory composition, but this change is much faster in the period when women are progressing from a regular cycle to menopause.

The age-related gradual decrease in the level of galactosylated IgG and the build-up of agalactosylated IgG is known to exacerbate low-grade chronic inflammation³²⁻³⁴ and acts as an effector of pro-inflammatory pathological changes^{35,36}. Decreased levels of IgG galactosylation and/or sialylation have been associated with a wide range of autoimmune conditions, such as systemic lupus erythematosus, inflammatory bowel disease, and many others. Changes in these IgG glycosylation traits are also associated with disease progression, disease activity, symptom severity, and response to treatment. In many cases, these changes occur before the onset of symptoms³⁷.

The rate of change from “young” to “old” IgG glycome increased significantly in the perimenopausal period, suggesting that the loss of immunosuppressive functions of IgG may be an underlying molecular mediator of at least some health risks in this period. The results of this study also indicate the potential of the IgG glycome composition as a biomarker for perimenopause. Perimenopause can last up to 15 years and is difficult to diagnose due to highly irregular hormonal cycles³⁸. As a result of poor awareness and inappropriate use of hormonal tests, women are often misdiagnosed with conditions such as fibromyalgia, migraines, depression, or chronic fatigue syndrome and are frequently prescribed antidepressants despite there being no evidence to support their use to improve the low mood associated with perimenopause or menopause³⁹. The importance of early diagnosis of perimenopause is supported by the research which has shown that early use of HRT leads to a greater reduction of future disease incidence as well as minimising the duration of symptoms⁴⁰.

Recent placebo-controlled randomised trials indicated the importance of estrogens in the regulation of IgG glycosylation^{15,41}, thus it seems quite probable that the decrease in estrogen levels is an important driver of changes in IgG glycosylation in perimenopause. Contrary to estrogens that have a very short half-life in circulation, IgG has a half-life of three weeks⁴², which implies that the current composition of the IgG glycome is affected by average concentrations of estrogen in the past 3-4 weeks. Since changes in the IgG glycome during perimenopause are so extensive, they could potentially be used as a diagnostic tool. In fact, IgG glycome composition could be used to determine long-term average concentrations of sex hormones in the same way glycated hemoglobin (HbA1c) is used to determine long-term concentrations of blood glucose.

Limitations of the study

The main limitation of this study is relatively long time between individual sampling time points (6.9 ± 2.6 years) that was not tailored for the occurrence of menopause. Therefore, in some cases, perimenopause was just a short part of the period in which the change in the IgG N-glycome occurred, while in others sampling might have occurred within the perimenopause period, with part of the perimenopause being before and another part after a specific sampling. Hopefully, a future study that would have more frequent sampling during the perimenopause period would enable an even more accurate assessment of IgG glycome association with perimenopause.

Conclusions

Changes in IgG glycosylation from “young” to “old” glycome associate with many health risks that accompany menopause¹. In some diseases like rheumatoid arthritis^{43,44} and cardiovascular diseases^{45,46} this change was shown to occur years before disease onset, suggesting the causal role of IgG glycans in disease development. Proinflammatory IgG glycome and the resulting decrease in the ability of IgG to suppress low-grade chronic inflammation may be an important molecular mechanism that mediates the increased health risk in perimenopause, thus this topic should be studied in more detail.

Competing interests

A patent covering all the main aspects of the use of IgG glycome as a predictor of menopause and perimenopause has been filed by Genos Ltd (application number: P20210509A). The application is currently pending. D.K., C.M., and G.L. are named as co-inventors on the patent application. G.L. is the founder and owner of Genos Ltd, a biotech company specialising in high-throughput glycomics that also has several patents in the field. H.D., A.Ci. T.P., and I.T.-A. are employees of Genos Ltd. The remaining authors declare no competing interests.

Acknowledgements

This study has been supported by the Croatian National Centre of Excellence in Personalised Healthcare (Contract no. KK.01.1.1.01.0010), ESI Funds grant for the Centre of Competences in Molecular Diagnostics and the Human Glycome Project. Equipment and products from Waters and New England Biolabs were used for this research. The Department of Twin Research receives support from grants from the Wellcome Trust (212904/Z/18/Z) and the Medical Research Council (MRC)/British Heart Foundation (BHF) Ancestry and Biological Informative Markers for Stratification of Hypertension (AIM-HY; MR/M016560/1), European Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd., the NIHR Clinical Research Facility and Biomedical Research Centre (based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London). C.M. is funded by the Chronic Disease Research Foundation and by the MRC AIM-HY project grant.

References

- 1 Martinić Kavur M, Lauc G, Pezer M. Systems Glycobiology: Immunoglobulin G Glycans as Biomarkers and Functional Effectors in Aging and Diseases. In: Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Elsevier, 2021. DOI:10.1016/b978-0-12-819475-1.00086-9.
- 2 Nimmerjahn F, Ravetch J V. Fcγ receptors as regulators of immune responses. *Nat Rev Immunol* 2008; **8**: 34–47.
- 3 Seeling M, Brückner C, Nimmerjahn F. Differential antibody glycosylation in autoimmunity: Sweet biomarker or modulator of disease activity? *Nat Rev Rheumatol* 2017; **13**: 621–30.
- 4 Ipsen-Escobedo A, Nimmerjahn F. More Rules, Still Exceptions: Understanding Immunomodulatory Antibody Activity In Vivo. *Cancer Cell* 2018; **33**: 545–6.
- 5 Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? *Nat Rev Immunol* 2013; **13**: 176–89.
- 6 Karsten CM, Pandey MK, Figge J, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIb and dectin-1. *Nat Med* 2012; **18**: 1401–6.
- 7 Nimmerjahn F, Ravetch J V. Anti-inflammatory actions of intravenous immunoglobulin. *Annu Rev Immunol* 2008; **26**: 513–33.
- 8 Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. *Nat. Rev. Endocrinol.* 2018; **14**: 576–90.
- 9 Pučić M, Knežević A, Vidič J, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. *Mol Cell Proteomics* 2011; **10**: M111.010090.
- 10 Menni C, Keser T, Mangino M, et al. Glycosylation of immunoglobulin G: Role of genetic and epigenetic influences. *PLoS One* 2013; **8**. DOI:10.1371/journal.pone.0082558.
- 11 Krištić J, Zaytseva OO, Ram R, et al. Profiling and genetic control of the murine immunoglobulin G glycome. *Nat Chem Biol* 2018; **14**: 516–24.
- 12 Shen X, Klarić L, Sharapov S, et al. Multivariate discovery and replication of five novel loci associated with Immunoglobulin G N-glycosylation. *Nat Commun* 2017; **8**. DOI:10.1038/s41467-017-00453-3.
- 13 Klaric L, Tsepilov YA, Stanton CM, et al. Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases. *Sci Adv* 2020; **6**. DOI:10.1126/sciadv.aax0301.
- 14 Lauc G, Huffman JE, Pučić M, et al. Loci Associated with N-Glycosylation of Human Immunoglobulin G Show Pleiotropy with Autoimmune Diseases and Haematological Cancers. *PLoS Genet* 2013; **9**. DOI:10.1371/journal.pgen.1003225.
- 15 Ercan A, Kohrt WM, Cui J, et al. Estrogens regulate glycosylation of IgG in women and men. *JCI Insight* 2017; **2**. DOI:10.1172/jci.insight.89703.
- 16 Juric J, Kohrt WM, Kifer D, et al. Effects of estradiol on biological age measured using the glycan age index. *AGING-US* 2020; **12**: 19756–65.
- 17 Krištić J, Vučković F, Menni C, et al. Glycans are a novel biomarker of chronological and biological ages. *Journals Gerontol - Ser A Biol Sci Med Sci* 2014; **69**: 779–89.
- 18 Stambuk J, Nakic N, Vuckovic F, et al. Global variability of the human IgG glycome.

AGING-US 2020; **12**: 15222–59.

19 Lobo RA, Davis SR, De Villiers TJ, *et al.* Prevention of diseases after menopause. *Climacteric* 2014; **17**: 540–56.

20 Verdi S, Abbasian G, Bowyer RCE, *et al.* TwinsUK: The UK Adult Twin Registry Update. *Twin Res Hum Genet* 2019; **22**: 523–9.

21 Trbojević-Akmačić I, Ugrina I, Lauc G. Comparative Analysis and Validation of Different Steps in Glycomics Studies. *Methods Enzymol* 2017; **586**: 37–55.

22 Agakova A, Vučković F, Klarić L, Lauc G, Agakov F. Automated integration of a UPLC glycomic profile. 2017 DOI:10.1007/978-1-4939-6493-2_17.

23 Keser T, Pavic T, Lauc G, Gornik O. Comparison of 2-aminobenzamide, procainamide and RapiFluor-MS as derivatizing agents for high-throughput HILIC-UPLC-FLR-MS N-glycan analysis. *Front Chem* 2018; **6**. DOI:10.3389/fchem.2018.00324.

24 Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* 2012; **28**: 882–3.

25 Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. *J Stat Softw* 2015; **67**. DOI:10.18637/jss.v067.i01.

26 Lenth R. emmeans: Estimated Marginal Means, aka Least-Squares Means. 2020.

27 Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. *J Stat Softw* 2010; **33**.

28 Kuhn M. caret: Classification and Regression Training. 2020.

29 Robin X, Turck N, Hainard A, *et al.* pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* 2011; **12**: 77.

30 R Core Team, Team RDC, R Core Team. R: A Language and Environment for Statistical Computing. 2020.

31 Gambacciani M, Cagnacci A, Lello S. Hormone replacement therapy and prevention of chronic conditions. *Climacteric*. 2019; **22**: 303–6.

32 Franceschi C, Bonafe M, Valensin S, *et al.* Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci* 2000; **908**: 244–54.

33 De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-aging and lifelong antigenic load as major determinants of ageing rate and longevity. *FEBS Lett* 2005; **579**: 2035–9.

34 Monti D, Ostan R, Borelli V, Castellani G, Franceschi C. Inflammaging and human longevity in the omics era. *Mech Ageing Dev* 2017; **165**: 129–38.

35 Franceschi C, Capri M, Monti D, *et al.* Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. *Mech Ageing Dev* 2007; **128**: 92–105.

36 Dall'Olio F, Vanhooren V, Chen CC, Slagboom PE, Wuhrer M, Franceschi C. N-glycomic biomarkers of biological aging and longevity: A link with inflammaging. *Ageing Res Rev* 2013; **12**: 685–98.

37 Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. *Cell Immunol* 2018; **333**: 65–79.

38 National Institute for Health and Care Excellence. Menopause: Diagnosis and Management. *Nice* 2015.

39 Leonhardt M. Low mood and depressive symptoms during perimenopause – Should General Practitioners prescribe hormone replacement therapy or antidepressants as the first-line treatment? *Post Reprod Heal* 2019; **25**: 124–30.

457 40 Ward K, Deneris A. An Update on Menopause Management. *J. Midwifery Women's*
458 *Heal.* 2018; **63**: 168–77.

459 41 Jurić J, Kohrt WM, Kifer D, *et al.* Effects of estradiol on biological age measured using
460 the glycan age index. *Aging (Albany NY)* 2020; **12**: 19756–65.

461 42 Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: From structure to
462 effector functions. *Front Immunol* 2014; **5**. DOI:10.3389/fimmu.2014.00520.

463 43 Gudelj I, Salo PP, Trbojević-Akmačić I, *et al.* Low galactosylation of IgG associates with
464 higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up.
465 *Biochim Biophys Acta - Mol Basis Dis* 2018. DOI:10.1016/j.bbadis.2018.03.018.

466 44 Ercan A, Cui J, Chatterton DE, *et al.* Aberrant IgG galactosylation precedes disease
467 onset, correlates with disease activity, and is prevalent in autoantibodies in
468 rheumatoid arthritis. *Arthritis Rheum* 2010; **62**: 2239–48.

469 45 Menni C, Gudelj I, MacDonald-Dunlop E, *et al.* Glycosylation Profile of
470 Immunoglobulin G Is Cross-Sectionally Associated with Cardiovascular Disease Risk
471 Score and Subclinical Atherosclerosis in Two Independent Cohorts. *Circ Res* 2018;
472 **122**: 1555–64.

473 46 Wittenbecher C, Štambuk T, Kuxhaus O, *et al.* Plasma N-glycans as emerging
474 biomarkers of cardiometabolic risk: A prospective investigation in the EPIC-Potsdam
475 cohort study. *Diabetes Care* 2020; **43**: 661–8.

476
477
478

Supplementary Tables and Figures

Supplementary Table 1. Descriptive information about the cohort

	Samples	Individuals	Families
Count, N	5354	2053	1173
- by sex (%)			
Male	274 (5)	113 (6)	69 (6)
Female	5080 (95)	1940 (94)	1104 (94)
- by group (%)			
Pre-menopause	1087 (21)	732	500
Menopause	3993 (79)	1678	969
- by age subset (%)			
Between 45 and 55 years	1374 (26)	1065 (52)	670 (57)
- by sex (%)			
Male	87 (6)	59 (6)	39 (6)
Female	1287 (94)	1006 (94)	631 (94)
- by group (%)			
Pre-menopause	507 (39)	453	340
Menopause	780 (61)	662	458
- by number of samples (%)			
One		203 (10)	
Two		399 (19)	
Three		1451 (71)	
Age in years, mean (SD)	58.3 (11.3)	57.6 (10.3)	57.2 (10.3)
- by sex			
Male	57.9 (11.7)	57.4 (10.8)	57.4 (10.9)
Female	58.3 (11.2)	57.6 (10.3)	57.2 (10.3)
- by group			
Pre-menopause	43.1 (7.1)	44.0 (6.0)	44.6 (5.9)
Menopause	62.4 (8.2)	61.7 (6.6)	61.3 (6.7)
- by age subset			
Between 45 and 55 years	50.6 (3.1)	50.7 (2.6)	50.6 (2.6)
- by sex			
Male	50.5 (3.1)	50.6 (2.6)	50.6 (2.5)
Female	50.6 (3.1)	50.7 (2.6)	50.6 (2.6)
- by group			
Pre-menopause	48.5 (2.6)	48.5 (2.4)	48.7 (2.4)
Menopause	51.9 (2.7)	52.2 (2.3)	52.0 (2.2)
Follow up time in years, mean (SD) between consecutive samples		6.94 (2.58)	
- by sex			
Male		7.17 (2.94)	
Female		6.93 (2.56)	
total follow up time		12.2 (4.3)	
- by sex			
Male		12.1 (4.8)	
Female		12.2 (4.3)	

Supplementary Table 2. Detailed description of glycan structures according to Keser et al.²³ corresponding to every individual immunoglobulin RapiFluor-MS glycan peak.*

<i>RapiFluor-MS glycan peak</i>	<i>Glycan structure</i>	<i>Description</i>	<i>Formula</i>
GP1	FA1	core fucosylated, monoantennary	GP1 / GP
GP2	A2	agalactosylated, biantennary	GP2 / GP
GP3	FA2; A2B	core fucosylated, biantennary (major); biantennary with bisecting GlcNAc (minor)	GP3 / GP
GP4	FA2B; M5	core fucosylated, biantennary with bisecting GlcNAc (major); oligomannose (minor)	GP4 / GP
GP5	A2[6]G1	monogalactosylated, biantennary	GP5 / GP
GP6	A2[3]G1	monogalactosylated, biantennary	GP6 / GP
GP7	FA2[6]G1	core fucosylated and monogalactosylated, biantennary	GP7 / GP
GP8	FA2[3]G1	core fucosylated and monogalactosylated, biantennary	GP8 / GP
GP9	FA2[6]BG1	core fucosylated and monogalactosylated, biantennary with bisecting GlcNAc	GP9 / GP
GP10	FA2[3]BG1	core fucosylated and monogalactosylated, biantennary with bisecting GlcNAc	GP10 / GP
GP11	A2G2	digalactosylated, biantennary	GP11 / GP
GP12	FA2G2; A2BG2	core fucosylated, digalactosylated, biantennary (major); digalactosylated, biantennary with bisecting GlcNAc (minor)	GP12 / GP
GP13	FA2BG2	core fucosylated, digalactosylated, biantennary with bisecting GlcNAc	GP13 / GP
GP14	FA2[6]G1S1; FA2[3]G1S1	core fucosylated, monogalactosylated and monosialylated biantennary; core fucosylated, monogalactosylated and monosialylated biantennary	GP14 / GP
GP15	A2G2S1	digalactosylated and monosialylated biantennary	GP15 / GP
GP16	FA2G2S1	core fucosylated, digalactosylated and monosialylated biantennary	GP16 / GP
GP17	FA2BG2S1	core fucosylated, digalactosylated and monosialylated biantennary with bisecting GlcNAc	GP17 / GP
GP18	n.d.	structure not determined	GP18 / GP
GP19	A2G2S2	digalactosylated and disialylated biantennary	GP19 / GP
GP20	A2BG2S2	digalactosylated and disialylated biantennary with bisecting GlcNAc	GP20 / GP
GP21	FA2G2S2	core fucosylated, digalactosylated and disialylated biantennary	GP21 / GP
GP22	FA2BG2S2	core fucosylated, digalactosylated and disialylated biantennary with bisecting GlcNAc	GP22 / GP

*structure abbreviations – all N-glycans have two core *N*-acetylglucosamines (GlcNAcs); F at the start of the abbreviation indicates a core-fucose α 1,6-linked to the inner GlcNAc; Mx, number (x) of mannose on core GlcNAcs; Ax, number of antenna (GlcNAc) on trimannosyl core; A2, biantennary with both GlcNAcs as β 1,2-linked; B, bisecting GlcNAc linked β 1,4 to β 1,3 mannose; G(x), number (x) of β 1,4 linked galactose on antenna; S(x), number (x) of sialic acids linked to galactose

Supplementary Table 3 Formulas used for the calculation of IgG derived traits

Structural feature	Formula
Agalactosylation (G0)	GP1+GP2+GP3+GP4
Monogalactosylation (G1)	GP5+GP6+GP7+GP8+GP9
Digalactosylation (G2)	GP10+GP11+GP12+GP13
Monosialylation (S1)	GP14+GP15+GP16+GP17
Disialylation (S2)	GP19+GP20+GP21+GP22
Incidence of bisecting GlcNAc (B)	GP4+GP9+GP10+GP13+GP17+GP20+GP22
Core fucosylation (CF)	GP1+GP3+GP4+GP7+GP8+GP9+GP10+GP12+GP13+GP14+GP16+GP17+GP21+GP22

Supplementary Figure 1 Representative HILIC-UPLC-FLR chromatographic profile of the immunoglobulin G RapiFluor-MS labelled N-glycome, with a graphic representation of the glycan structures corresponding to each glycan peak (GP). In case of multiple structures per GP, the upper structure is the major one, and the lower one is minor in abundance.

Supplementary Figure 2. IgG glycome composition in premenopausal and menopausal women, and men. Mean glycan abundances (% of total IgG N-glycome) and corresponding 95% confidence intervals were estimated from fitted mixed model with logit transformed glycan as dependent variable and sex, menopausal status (nested within sex), age and age-menopausal status interaction as fixed factors, as well as family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p values less than 0.1 are shown.

Supplementary Figure 3. Average annual change of IgG glycans in females during the perimenopause period, females in pre- or post-menopause, and males. Mean yearly change in glycan abundances and corresponding 95% confidence intervals were estimated from fitted mixed model with logit transformed glycan as dependent variable and sex, menopausal status (nested within sex), age and age-menopausal status interaction as fixed factors, as well as family ID and individual ID (nested within family ID) as random intercepts and age as random slope. Only adjusted post-hoc p values less than 0.1 are shown.